Price Wealth LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 388.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,244 shares of the biopharmaceutical company’s stock after purchasing an additional 6,555 shares during the quarter. Price Wealth LLC’s holdings in Pfizer were worth $303,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. State Street Corp grew its holdings in Pfizer by 0.3% in the 1st quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock worth $9,551,162,000 after acquiring an additional 830,299 shares during the last quarter. Maverick Capital Ltd. bought a new position in Pfizer during the 1st quarter valued at approximately $297,000. APG Asset Management N.V. lifted its holdings in Pfizer by 129.4% in the 1st quarter. APG Asset Management N.V. now owns 6,955,829 shares of the biopharmaceutical company’s stock worth $227,038,000 after buying an additional 3,924,241 shares during the period. Cox Capital Mgt LLC grew its position in shares of Pfizer by 4.1% in the 2nd quarter. Cox Capital Mgt LLC now owns 54,196 shares of the biopharmaceutical company’s stock worth $1,772,000 after buying an additional 2,133 shares during the last quarter. Finally, Modus Advisors LLC increased its stake in shares of Pfizer by 67.6% during the second quarter. Modus Advisors LLC now owns 28,458 shares of the biopharmaceutical company’s stock valued at $931,000 after buying an additional 11,477 shares during the period. Hedge funds and other institutional investors own 69.08% of the company’s stock.
Several analysts recently weighed in on the stock. Mizuho reiterated a “buy” rating and issued a $43.00 price target on shares of Pfizer in a report on Tuesday, September 15th. Atlantic Securities cut Pfizer from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $44.00 to $39.00 in a research report on Monday, October 12th. UBS Group increased their price objective on Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Wednesday, July 29th. Berenberg Bank began coverage on Pfizer in a research report on Tuesday, September 29th. They set a “hold” rating and a $38.00 price objective for the company. Finally, Royal Bank of Canada set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Friday, October 16th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the stock. Pfizer currently has an average rating of “Hold” and an average target price of $39.81.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The business had revenue of $11.80 billion during the quarter, compared to the consensus estimate of $11.55 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.80 EPS. Analysts anticipate that Pfizer Inc. will post 2.84 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be paid a dividend of $0.38 per share. The ex-dividend date is Thursday, November 5th. This represents a $1.52 annualized dividend and a yield of 3.98%. Pfizer’s payout ratio is 51.53%.
In related news, Director Ronald E. Blaylock purchased 13,000 shares of Pfizer stock in a transaction on Thursday, August 6th. The shares were bought at an average cost of $38.55 per share, for a total transaction of $501,150.00. Following the acquisition, the director now owns 4,000 shares in the company, valued at approximately $154,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.08% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: What’s a Black Swan?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.